Earl Ray Dorsey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4856494/publications.pdf

Version: 2024-02-01

129 14,357 44 112
papers citations h-index g-index

134 134 134 134 18443

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Remote smartphone monitoring of Parkinson's disease and individual response to therapy. Nature Biotechnology, 2022, 40, 480-487.	17.5	73
2	Preventing Parkinson's Disease: An Environmental Agenda. Journal of Parkinson's Disease, 2022, 12, 45-68.	2.8	45
3	Recruitment for Remote Decentralized Studies in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 371-380.	2.8	12
4	A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study. Digital Biomarkers, 2022, 6, 1-8.	4.4	6
5	Metadata Framework to Support Deployment of Digital Health Technologies in Clinical Trials in Parkinson's Disease. Sensors, 2022, 22, 2136.	3 . 8	7
6	Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. American Journal of Human Genetics, 2022, 109, 885-899.	6.2	29
7	The Huntington's Disease Health Index: Initial Evaluation of a Disease-Specific Patient Reported Outcome Measure. Journal of Huntington's Disease, 2022, 11, 217-226.	1.9	2
8	Identifying and characterising sources of variability in digital outcome measures in Parkinson's disease. Npj Digital Medicine, 2022, 5, .	10.9	5
9	Design of a virtual longitudinal observational study in Parkinson's disease (ATâ€HOME PD). Annals of Clinical and Translational Neurology, 2021, 8, 308-320.	3.7	18
10	Detecting Parkinson Disease Using a Web-Based Speech Task: Observational Study. Journal of Medical Internet Research, 2021, 23, e26305.	4.3	15
11	Development of digital measures for nighttime scratch and sleep using wrist-worn wearable devices. Npj Digital Medicine, 2021, 4, 42.	10.9	20
12	Crowdsourcing digital health measures to predict Parkinson's disease severity: the Parkinson's Disease Digital Biomarker DREAM Challenge. Npj Digital Medicine, 2021, 4, 53.	10.9	24
13	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease, 2021, 7, 16.	5.3	10
14	Improving Access to Care: Telemedicine Across Medical Domains. Annual Review of Public Health, 2021, 42, 463-481.	17.4	98
15	The triple aim of clinical research. Clinical Trials, 2021, 18, 511-513.	1.6	6
16	GEORGE®: A Pilot Study of a Smartphone Application for Huntington's Disease. Journal of Huntington's Disease, 2021, 10, 293-301.	1.9	11
17	Bad Air and Parkinson Disease—The Fog May Be Lifting. JAMA Neurology, 2021, 78, 793.	9.0	4
18	The new platforms of health care. Npj Digital Medicine, 2021, 4, 112.	10.9	11

#	Article	IF	CITATIONS
19	Using Technology to Reshape Clinical Care and Research in Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, S1-S3.	2.8	3
20	A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. Journal of Medical Internet Research, 2021, 23, e29511.	4.3	1
21	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	2.2	9
22	Practicing in a Pandemic. Neurology: Clinical Practice, 2021, 11, e179-e188.	1.6	15
23	A real-world study of wearable sensors in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 106.	5.3	24
24	Symptom burden among individuals with Parkinson disease. Neurology: Clinical Practice, 2020, 10, 65-72.	1.6	29
25	Advancing the Use of Mobile Technologies in Clinical Trials: Recommendations from the Clinical Trials Transformation Initiative. Digital Biomarkers, 2020, 3, 145-154.	4.4	47
26	Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond. Journal of Parkinson's Disease, 2020, 10, 1379-1382.	2.8	27
27	A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders. Movement Disorders, 2020, 35, 1897-1902.	3.9	37
28	The New Normal in Clinical Trials: Decentralized Studies. Annals of Neurology, 2020, 88, 863-866.	5.3	45
29	Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1779-1786.	2.8	33
30	Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. Neurology: Clinical Practice, 2020, 10, 7-14.	1.6	15
31	A Longitudinal Wearable Sensor Study in Huntington's Disease. Journal of Huntington's Disease, 2020, 9, 69-81.	1.9	19
32	Direct-to-consumer digital health. The Lancet Digital Health, 2020, 2, e163-e165.	12.3	27
33	Patient-reported impact of symptoms in Huntington disease. Neurology, 2020, 94, e2045-e2053.	1.1	37
34	Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C's that Will Shape the Future of Telemedicine. Journal of Parkinson's Disease, 2020, 10, 893-897.	2.8	70
35	Telemedicine 2020 and the next decade. Lancet, The, 2020, 395, 859.	13.7	196
36	A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design. Journal of Parkinson's Disease, 2020, 10, 1195-1207.	2.8	8

#	Article	IF	CITATIONS
37	The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders. JAMA Neurology, 2020, 77, 927.	9.0	183
38	Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. Lancet Neurology, The, 2020, 19, 623-634.	10.2	110
39	Spatio-Temporal Attention and Magnification for Classification of Parkinson's Disease from Videos Collected via the Internet. , 2020, , .		5
40	Deep Phenotyping of Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 855-873.	2.8	42
41	Predicting Parkinson's Disease with Multimodal Irregularly Collected Longitudinal Smartphone Data. , 2020, , .		1
42	Cost vs care. Neurology, 2019, 93, 985-986.	1.1	1
43	The PARK Framework for Automated Analysis of Parkinson's Disease Characteristics., 2019, 3, 1-22.		28
44	Patient Views on Telemedicine for Parkinson Disease. Journal of Parkinson's Disease, 2019, 9, 401-404.	2.8	49
45	Passive Monitoring at Home: A Pilot Study in Parkinson Disease. Digital Biomarkers, 2019, 3, 22-30.	4.4	36
46	A roadmap for implementation of patientâ€entered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders, 2019, 34, 657-663.	3.9	213
47	The Parkinson's disease eâ€diary: Developing a clinical and research tool for the digital age. Movement Disorders, 2019, 34, 676-681.	3.9	43
48	Teleneurology and mobile technologies: the future of neurological care. Nature Reviews Neurology, 2018, 14, 285-297.	10.1	173
49	The State of US Health, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 319, 1444.	7.4	1,042
50	Telemedicine for Parkinson's Disease: Limited Engagement Between Local Clinicians and Remote Specialists. Telemedicine Journal and E-Health, 2018, 24, 722-724.	2.8	13
51	Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity. JAMA Neurology, 2018, 75, 876.	9.0	303
52	Telemedicine Use for Movement Disorders: A Global Survey. Telemedicine Journal and E-Health, 2018, 24, 979-992.	2.8	22
53	The Parkinson Pandemic—A Call to Action. JAMA Neurology, 2018, 75, 9.	9.0	584
54	Patient and Physician Perceptions of Virtual Visits for Parkinson's Disease: A Qualitative Study. Telemedicine Journal and E-Health, 2018, 24, 255-267.	2.8	69

#	Article	IF	Citations
55	The Best Digital Biomarkers Papers of 2017. Digital Biomarkers, 2018, 2, 64-73.	4.4	12
56	The Emerging Evidence of the Parkinson Pandemic. Journal of Parkinson's Disease, 2018, 8, S3-S8.	2.8	770
57	Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 939-953.	10.2	1,573
58	Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews Drug Discovery, 2018, 17, 729-750.	46.4	117
59	The Use of Smartphones for Health Research. Academic Medicine, 2017, 92, 157-160.	1.6	138
60	Opinion and Special Articles: Loan forgiveness options for young neurologists. Neurology, 2017, 88, e153-e156.	1.1	3
61	Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action. Clinical Therapeutics, 2017, 39, 1064-1076.	2.5	40
62	Comment: The virtual neurologist. Neurology, 2017, 89, 161-161.	1.1	0
63	Distribution of Medical Education Debt by Specialty, 2010-2016. JAMA Internal Medicine, 2017, 177, 1532.	5.1	38
64	Virtual visits for Parkinson disease. Neurology: Clinical Practice, 2017, 7, 283-295.	1.6	35
65	National randomized controlled trial of virtual house calls for Parkinson disease. Neurology, 2017, 89, 1152-1161.	1.1	169
66	Telehealth Management of Parkinson's Disease Using Wearable Sensors: An Exploratory Study. Digital Biomarkers, 2017, 1, 43-51.	4.4	45
67	Multiple Wearable Sensors in Parkinson and Huntington Disease Individuals: A Pilot Study in Clinic and at Home. Digital Biomarkers, 2017, 1, 52-63.	4.4	1,794
68	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology, 2017, 89, 2495-2502.	1.1	97
69	The First Frontier: Digital Biomarkers for Neurodegenerative Disorders. Digital Biomarkers, 2017, 1, 6-13.	4.4	100
70	Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases. Patient, 2017, 10, 541-544.	2.7	10
71	A Digital Journal for a Digital Era. Digital Biomarkers, 2017, 1, 1-3.	4.4	7
72	The Inaugural Issue. Digital Biomarkers, 2017, 1, , sgmppl =-5.	4.4	0

#	Article	IF	CITATIONS
73	Next Generation House Call. Cerebrum: the Dana Forum on Brain Science, 2017, 2017, .	0.1	O
74	Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 2016, 31, 1272-1282.	3.9	464
75	Neurologic care anytime?. Neurology: Clinical Practice, 2016, 6, 472-474.	1.6	2
76	Hospital care for mental health and substance abuse conditions in Parkinson's disease. Movement Disorders, 2016, 31, 1810-1819.	3.9	14
77	Forgiven but not Relieved: US Physician Workforce Consequences of Changes to Public Service Loan Forgiveness. Journal of General Internal Medicine, 2016, 31, 1237-1241.	2.6	21
78	Smartphones as new tools in the management and understanding of Parkinson's disease. Npj Parkinson's Disease, 2016, 2, 16006.	5.3	27
79	Silent majority. Neurology: Clinical Practice, 2016, 6, 11-13.	1.6	0
80	State of Telehealth. New England Journal of Medicine, 2016, 375, 1399-1400.	27.0	37
81	Wearable Sensors in Huntington Disease: A Pilot Study. Journal of Huntington's Disease, 2016, 5, 199-206.	1.9	52
82	Moving Parkinson care to the home. Movement Disorders, 2016, 31, 1258-1262.	3.9	94
83			
	State of Telehealth. New England Journal of Medicine, 2016, 375, 154-161.	27.0	882
84	State of Telehealth. New England Journal of Medicine, 2016, 375, 154-161. The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011.	27.0 5.3	439
84	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3,		
	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011. Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum.	5.3	439
85	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011. Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum. American Economic Review, 2016, 106, 1562-1565.	5.3 8.5	439 17
85	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011. Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum. American Economic Review, 2016, 106, 1562-1565. The McDonaldization of Medicine. JAMA Neurology, 2016, 73, 15. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease:	5.3 8.5 9.0	439 17 29
85 86 87	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011. Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum. American Economic Review, 2016, 106, 1562-1565. The McDonaldization of Medicine. JAMA Neurology, 2016, 73, 15. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemedicine Journal and E-Health, 2016, 22, 590-598.	5.3 8.5 9.0 2.8	439 17 29 47

#	Article	IF	CITATIONS
91	Informativeness of Early Huntington DiseaseÂSignsÂaboutÂGeneÂStatus. Journal of Huntington's Disease, 2015, 4, 271-277.	1.9	5
92	Feasibility of Virtual Research Visits inÂFoxÂTrial Finder. Journal of Parkinson's Disease, 2015, 5, 505-515.	2.8	50
93	The Anatomy of Medical Research. JAMA - Journal of the American Medical Association, 2015, 313, 174.	7.4	342
94	Novel Methods and Technologies for 21st-Century Clinical Trials. JAMA Neurology, 2015, 72, 582.	9.0	95
95	Nursing home and end-of-life care in Parkinson disease. Neurology, 2015, 85, 413-419.	1.1	87
96	United States trends in thrombolysis for older adults with acute ischemic stroke. Clinical Neurology and Neurosurgery, 2015, 139, 16-23.	1.4	8
97	Telemedicine and Parkinson's Disease. , 2015, , 105-112.		0
98	Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials, 2014, 15, 465.	1.6	25
99	Impact of 2011 Resident Duty Hour Requirements on Neurology Residency Programs and Departments. Neurohospitalist, The, 2014, 4, 119-126.	0.8	7
100	Virtual visits for Parkinson disease. Neurology: Clinical Practice, 2014, 4, 146-152.	1.6	52
101	Neurohospitalists: Perceived Need and Training Requirements in Academic Neurology. Neurohospitalist, The, 2014, 4, 9-17.	0.8	9
102	An Update on Parkinson's Disease: Improving Patient Outcomes. American Journal of Medicine, 2014, 127, S3.	1.5	20
103	The past, present, and future of telemedicine for Parkinson's disease. Movement Disorders, 2014, 29, 871-883.	3.9	141
104	A Pilot Study of Virtual Visits in Huntington Disease. Journal of Huntington's Disease, 2014, 3, 189-195.	1.9	47
105	The Anatomy of Health Care in the United States. JAMA - Journal of the American Medical Association, 2013, 310, 1947.	7.4	257
106	Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease. American Economic Review, 2013, 103, 804-830.	8.5	201
107	Limited Life Expectancy, Human Capital and Health Investments. American Economic Review, 2013, 103, 1977-2002.	8.5	108
108	The coming crisis. Neurology, 2013, 80, 1989-1996.	1.1	144

#	Article	IF	Citations
109	Natural History of Huntington Disease. JAMA Neurology, 2013, 70, 1520-30.	9.0	84
110	Choosing Wisely. Neurology, 2013, 81, 946-947.	1.1	3
111	Caring for the majority. Movement Disorders, 2013, 28, 261-262.	3.9	10
112	Randomized Controlled Clinical Trial of "Virtual House Calls―for Parkinson Disease. JAMA Neurology, 2013, 70, 565.	9.0	201
113	Depressed Mood and Suicidality in Individuals Exposed to Tetrabenazine in a Large Huntington Disease Observational Study. Journal of Huntington's Disease, 2013, 2, 509-515.	1.9	15
114	Telemedicine in Leading US Neurology Departments. Neurohospitalist, The, 2012, 2, 123-128.	0.8	57
115	Commentary: Improving the Supply and Distribution of Primary Care Physicians. Academic Medicine, 2011, 86, 541-543.	1.6	15
116	A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. Archives of Neurology, 2010, 67, 154.	4.5	87
117	Increasing access to specialty care: A pilot, randomized controlled trial of telemedicine for Parkinson's disease. Movement Disorders, 2010, 25, 1652-1659.	3.9	153
118	A U.S. survey of patients with Parkinson's disease: Satisfaction with medical care and support groups. Movement Disorders, 2010, 25, 2128-2135.	3.9	45
119	Impact of FDA Black Box Advisory on Antipsychotic Medication Use. Archives of Internal Medicine, 2010, 170, 96.	3.8	211
120	Funding of US Biomedical Research, 2003-2008. JAMA - Journal of the American Medical Association, 2010, 303, 137.	7.4	291
121	Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas. PLoS ONE, 2009, 4, e7015.	2.5	44
122	Funding of Parkinson research from industry and US federal and foundation sources. Movement Disorders, 2009, 24, 731-737.	3.9	6
123	Telemedicine for the care of nursing home residents with Parkinson's disease. Movement Disorders, 2009, 24, 1073-1076.	3.9	52
124	The Economics of New Faculty Hires in Basic Science. Academic Medicine, 2009, 84, 26-31.	1.6	22
125	Communicating Clinical Trial Results to Research Participants. Archives of Neurology, 2008, 65, 1590.	4.5	28
126	Biomarkers in Parkinson's disease. Expert Review of Neurotherapeutics, 2006, 6, 823-831.	2.8	23

#	Article	IF	CITATIONS
127	Financial anatomy of neuroscience research. Annals of Neurology, 2006, 60, 652-659.	5.3	46
128	An Evaluation of Four Proposals to Reduce the Financial Burden of Medical Education. Academic Medicine, 2006, 81, 245-251.	1.6	25
129	The Influence of Controllable Lifestyle and Sex on the Specialty Choices of Graduating U.S. Medical Students, 1996???2003. Academic Medicine, 2005, 80, 791-796.	1.6	251